Fusion Protein Technologies for Biopharmaceuticals

Applications and Challenges

Nonfiction, Health & Well Being, Medical, Medical Science, Biotechnology, Science & Nature, Science, Other Sciences, Molecular Biology, Pharmacology
Cover of the book Fusion Protein Technologies for Biopharmaceuticals by , Wiley
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9781118354582
Publisher: Wiley Publication: January 28, 2013
Imprint: Wiley Language: English
Author:
ISBN: 9781118354582
Publisher: Wiley
Publication: January 28, 2013
Imprint: Wiley
Language: English

The state of the art in biopharmaceutical FUSION PROTEIN DESIGN

Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched.

Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs.

The book covers the major types of fusion proteins—receptor-traps, immunotoxins, Fc-fusions and peptibodies—while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies.

Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

The state of the art in biopharmaceutical FUSION PROTEIN DESIGN

Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched.

Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs.

The book covers the major types of fusion proteins—receptor-traps, immunotoxins, Fc-fusions and peptibodies—while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies.

Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.

More books from Wiley

Cover of the book The Handbook of Plant Metabolomics by
Cover of the book Living Vegetarian For Dummies by
Cover of the book Math For Real Life For Dummies by
Cover of the book Designing Urban Agriculture by
Cover of the book Modern Methods in Stereoselective Aldol Reactions by
Cover of the book Mathematical Statistics with Resampling and R by
Cover of the book A History of Interest Rates by
Cover of the book The Chemical Element by
Cover of the book The Food Industry Innovation School by
Cover of the book The Project Manager's Guide to Mastering Agile by
Cover of the book The Bullseye Principle by
Cover of the book Staatsorganisationsrecht I für Dummies by
Cover of the book A Companion to François Truffaut by
Cover of the book A Companion to Greek and Roman Political Thought by
Cover of the book Fundamental Analysis and Position Trading by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy